Navigation Links
Upending textbook science on Alzheimer's disease
Date:11/23/2009

Alzheimer's disease is caused by the build-up of a brain peptide called amyloid-beta. That's why eliminating the protein has been the focus of almost all drug research pursuing a cure for the devastating neurodegenerative condition.

But that may be counterproductive, says Dr. Inna Slutsky of Tel Aviv University's Department of Physiology and Pharmacology, Sackler Faculty of Medicine. Her recent research demonstrates that amyloid-beta is also necessary to maintain proper brain functioning.

These findings may shake the foundations of Alzheimer's research.

In a new study published this month in Nature Neuroscience, Dr. Slutsky finds that amyloid-beta is essential for normal day-to-day information transfer through nerve cell networks in the brain. "If this protein is removed from the brain," says Dr. Slutsky, "as some drugs in development attempt to do, it may cause an impairment of neuronal function, as well as a further and faster accumulation of amyloid-betain Alzheimer's."

A reset button for drug researchers

Without amyloid-beta, a normal product of cellular metabolism, one's ability to learn and remember could be profoundly damaged, so drugs currently in development to eliminate amyloid-beta could be rendered obsolete. With Dr. Slutsky's research, a leap in understanding the cause and development of Alzheimer's disease, however, new, more effective drug therapies could be developed.

By studying synapses in brain slices of healthy mice and in neuronal networks growing in vitro, Dr. Slutsky and her team determined that there is an optimal amount of amyloid-beta needed to keep the neurons working well. Her students Efrat Abramov and Iftach Dolev found that if this precise balance is even slightly disturbed, the effectiveness of information transfer between neurons is greatly impaired.

"Synapses where neurons meet work as filters of information," says Dr. Slutsky. "What is really exciting for us is the fact that amyloid-beta peptide, believed to be toxic, regulates the type of information that neurons transfer."

A new way to prevent Alzheimer's?

The study of Dr. Slutsky's team suggests that the amyloid-beta protein belongs to endogenous molecules regulating normal synaptic transmission in the hippocampus, a brain region involved in learning and memory function. "There is a long list of neuromodulators that help synapses optimize information transfer," she says. "Intriguingly, amyloid-beta seems to be able to modulate this filter and shape its properties."

The new study is discouraging news for those Alzheimer drugs that attempt to block or remove the amyloid-beta aggregation process currently in clinical trials, Dr. Slutsky believes. "Our data shows that after the release of amyloid-beta, synaptic activity in the neurons is increased through a positive feedback loop. Disrupting this positive feedback loop, I believe, is the key for prevention of the earliest signs of Alzheimer's."


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related medicine news :

1. Many Ob-Gyn Textbooks Lack Good Info on Breast-Feeding
2. Rising Medical Solutions and CEO Are Featured as a Case Study in the Effective Small Business Management, Ninth Edition Textbook
3. Landmark textbook on strokes in children and young adults updated in second edition
4. UTSA Dean George Perry co-edits textbook chronicling four decades of Alzheimers research
5. Living Medical Textbook(TM) from Projects In Knowledge(R)
6. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
11. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... VEGAS, NEV. (PRWEB) , ... August 22, 2017 ... ... American Academy of Anti-Aging Medicine recently spoke at a popular international aesthetics conference ... therapy has had on restoring his patients’ health and his growing practice. , ...
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, ... replacement of auto glass for most makes and models, in Grand Prairie, TX, located in ... , They have been a family owned business for the past 40 years with 32 ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Glimpses Of Light”: is a unique ... Of Light” is the creation of published author, J.M. Shepherd, a writer, teacher, traveler, ... to life’s perplexing mysteries. , Shepherd shares, “Love is one of the least understood ...
(Date:8/21/2017)... ... 22, 2017 , ... PracticeMatch, a company that provides online resources , ... and advanced practitioners like nurse practitioners and physician assistants , will ... of this year. The online career fairs will allow job seekers to connect with ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... today announced that it has become the Official Technology Partner of North Country ... AES (Advanced Event Systems) volleyball software, along with providing sport management software ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: